Patent 7,696,236 Overview and Landscape Analysis
What does Patent 7,696,236 cover?
Patent 7,696,236, filed by Eli Lilly and Company, was granted in 2010. It covers a class of compounds and their pharmaceutical uses, specifically agents related to orexin receptor antagonists. The patent claims focus on the chemical structures, compositions, and methods of inhibiting orexin receptors, primarily targeting sleep disorders such as insomnia.
Scope of Claims
The patent's claims can be classified into three categories:
-
Compound claims: Cover specific chemical structures of orexin receptor antagonists, including heterocyclic core structures with specified substitutions. These claim broad derivatives within a defined chemical space, aiming to capture a wide range of compounds.
-
Method claims: Cover methods of using the compounds to treat sleep-related disorders, including administration routes, dosages, and formulations.
-
Composition claims: Encompass pharmaceutical compositions combining the compounds with pharmaceutically acceptable carriers or excipients.
Key Claim Elements
- Chemical structures: Include compounds with a central heterocyclic core attached to various substituents, with specific structural limitations and optional modifications.
- Methods of treatment: Administering the compounds at effective doses to improve sleep parameters in mammals.
- Pharmaceutical compositions: Combining the compounds with carriers to prepare tablets, capsules, or liquid formulations.
Claim breadth and limitations
The patent's claims are broad but structured to focus on particular chemical scaffolds. The chemical claims cover multiple substitutions, but specific motifs are consistent across claims, indicating a balance between scope and specificity. The method claims are narrow, primarily covering administration for sleep disorders.
Patent landscape surrounding Patent 7,696,236
The patent landscape around Patent 7,696,236 indicates a focus on orexin receptor antagonists and sleep disorder therapeutics.
Key players
- Eli Lilly: Original assignee with the patent, holding key compound and method claims.
- Competitors: Companies such as Merck, Allergan, and Ivaca Pharma hold patents on orexin receptor antagonists or similar sleep aids, creating a dense patent thicket.
Related patents and developments
- Orexin receptor antagonist patents: Multiple filings from Eli Lilly and rivals, with compounds similar in chemical class, such as suvorexant (Belsomra), a drug marketed by Merck.
- Research publications: Scholars have published extensive data on orexin receptor pharmacology, influencing subsequent patent filings.
Patent family and expiration
The patent family includes continuation and continuation-in-part applications, extending legal protection and modifying claims. The patent's expiration date is March 2028, assuming no regulatory extensions.
Infringement and freedom-to-operate considerations
Given its broad compound claims, Patent 7,696,236 potentially blocks competitors from developing similar orexin antagonists within the chemical space claimed. Manufacturers focusing on sleep disorder therapeutics should carefully assess this patent when developing new compounds.
Strategies for navigating the landscape include
- Designing compounds outside the claimed chemical structures.
- Developing new formulations or methods not covered explicitly in the patent.
- Licensing or partnering with patent holders.
Regulatory and legal context
The patent's claims hold enforceability in U.S. courts, and its coverage aligns with FDA-approved indications for sleep disorders. The patent's scope does not directly cover the drug's commercial formulation but shields the active compounds and their therapeutic uses.
Summary
Patent 7,696,236 covers a substantial chemical class of orexin receptor antagonists with method and composition claims aimed at sleep disorder treatment. Its broad compound claims and strategic patent family management protect Eli Lilly's interests while shaping the competitive landscape for orexin-based therapeutics.
Key Takeaways
- The patent claims a wide scope of heterocyclic compounds targeting orexin receptors.
- It covers methods of treatment for sleep disorders and pharmaceutical compositions.
- The patent landscape is dense with similar compounds from competitors, notably Merck’s suvorexant.
- Expiry is projected for 2028, but existing patent families and continuation filings could extend protection.
- Entry barriers remain high for competitors due to broad claims and strategic patent positioning.
FAQs
1. Does Patent 7,696,236 cover specific drugs on the market?
It covers many chemical compounds within the orexin receptor antagonist class. Suvorexant (Belsomra), marketed by Merck, is related but not directly covered unless identical compounds are used.
2. Can competitors develop orexin receptor antagonists without infringing?
Yes. Designing compounds outside the patent’s specific chemical claims or claiming novel mechanisms can avoid infringement.
3. Are there innovative strategies to circumvent this patent?
Focusing on different chemical scaffolds or formulations, or attempting to challenge the patent's validity, are common strategies.
4. What is the patent’s expiration date?
March 2028, assuming no extensions or legal challenges.
5. How does this patent influence future drug development?
It creates a barrier for generic development within its chemical scope but also guides researchers toward novel chemical spaces or alternative therapeutic targets.
References
- Eli Lilly and Company. (2010). Patent 7,696,236. United States Patent and Trademark Office.
- FDA. (2022). Belsomra (suvorexant) prescribing information.
- Tham, C. K., & Haniffa, S. (2014). Pharmacology and toxicology of orexin receptor antagonists. Drug Discovery Today, 19(11), 1119–1124.
[1] U.S. Patent and Trademark Office. Patent 7,696,236.
